Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population

New England Journal of Medicine

Volumn 351, Issue 26, 2004, Pages 2704-2714

  Imperiale, Thomas F ^a,f   Ransohoff, David F ^b   Itzkowitz, Steven H ^c   Turnbull, Barry A ^d   Ross, Michael E ^e  

^a INDIANA UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Care Stat   (United States)

^e Exact Sciences Corporation   (United States)

^f REGENSTRIEF INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DNA DETERMINATION; DYSPLASIA; FECES; FECES ANALYSIS; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; POLYP; PRIORITY JOURNAL;

ADENOCARCINOMA; ADENOMA; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; COLONOSCOPY; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FECES; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MUTATION; OCCULT BLOOD; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 10844281210     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa033403     Document Type: Article

References (36)

1. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003;53:27-43.
2. Ransohoff DF, Sandler RS. Screening for colorectal cancer. N Engl J Med 2002;346: 40-4.
3. Ahluwalia IB, Mack KA, Murphy W, Mokdad AH, Bales VS. State-specific prevalence of selected chronic disease-related characteristics - Behavioral Risk Factor Surveillance System, 2001. MMWR Surveill Summ 2003;52:1-80.
4. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7.
5. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood: Minnesota Colonoscopy Cancer Control Study. N Engl J Med 1993;328:1365-71. [Erratum, N Engl J Med 1993;329:672.]
6. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test Lancet 1996;348: 1467-71.
7. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
8. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-5.
9. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002;315:157-68.
10. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-7.
11. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-9.
12. Koornstra JJ, de Jong S, Hollema H, de Vries EG, Kleibeuker JH. Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol 2003;45:37-53.
13. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-27.
14. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-65.
15. Syngal S, Chung D, Willet C, et al. The loss of stool DNA mutation abnormalities in colorectal neoplasia after treatment Gastroenterology 2003;124:Suppl 1:A-5. abstract
16. Tagore KS, Lawson MJ, Yucaitis JA, et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003;3:47-53.
17. Traverso G, Shuber A, Levin B, et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002;346:311-20.
18. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology 2003;124:544-60.
19. Suggested technique for fecal occult blood testing and interpretation in colorectal cancer screening. Ann Intern Med 1997; 126:808-10.
20. Ransohoff DF, Lang CA. Screening for colorectal cancer with the fecal occult blood test a background paper. Ann Intern Med 1997;128:811-22.
21. McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika 1947;12:153-7.
22. Calistri D, Rengucci C, Bocchini R, Saragoni L, Zoli W, Amadori D. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol 2003;1: 377-83.
23. Traverso G, Shuber A, Olsson L, et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002; 359:403-4.
24. Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer: Veterans Affairs Cooperarive Study Group 380. N Engl J Med 2000; 343:162-8. [Erratum, N Engl J Med 2000; 343:1204.]
25. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345:555-60.
26. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Ann Intern Med 2003;139:959-65.
27. Pinsky PF, Schoen RE, Weissfeld JL, Bresalier RS, Hayes RB, Gohagan JK. Predictors of advanced proximal neoplasia in persons with abnormal screening flexible sigmoidoscopy. Clin Gastroenterol Hepatol 2003;1:103-10.
28. Schoen RE, Pinsky PF, Weissfeld JL, et al. Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA 2003; 290:41-8.
29. Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol 2000;31:51-7.
30. Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia: a prospective study using Hemoccult and HemoQuant tests. JAMA 1993;269:1262-7.
31. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996;334:155-9.
32. Whitney D, Skoletsky J, Moore K, et al. Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test J Mol Diagn 2004;6:386-95.
33. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:96-104.
34. U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med 2002; 137:129-31.
35. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:132-41.
36. Ransohoff DF. Virtual colonoscopy - what it can do vs what it will do. JAMA 2004; 291:1772-4.